论文部分内容阅读
过继免疫疗法抗肿瘤作用已被确认,但大剂量输入rIL-2和LAK细胞常引起严重副作用,且预防肝癌局部复发及转移的效果并不确切。作者的研究对象是北海道大学医学部外科手术切除脾的30例肝癌病人,其中15例行免疫治疗(男12例,女3例),平均年龄58.6岁,其中4例HBS抗原阳性,5例ICG(R15)值在20%以上。15例行单纯化疗(男14例,女1例),平均年龄56.9岁,3例HBS抗原阳性,3例ICG值20%以上。全组60%合并肝硬变,免疫治疗组高于化疗组;合并食管静脉曲张前者1例,后者3例。研究首先对新鲜脾细胞进行LAK细胞诱导,然后
The anti-tumor effect of adoptive immunotherapy has been confirmed, but large doses of rIL-2 and LAK cells often cause serious side effects, and the effect of preventing local recurrence and metastasis of liver cancer is not clear. The authors studied 30 patients with liver cancer who underwent surgical resection of the spleen from the Department of Medicine, Hokkaido University. Among them, 15 patients received immunotherapy (12 males and 3 females) with an average age of 58.6 years, of which 4 were positive for HBS antigen and 5 ICG ( R15) is above 20%. In 15 patients who underwent chemotherapy alone (male 14 and female 1), the average age was 56.9 years. Three cases were positive for HBS antigen and 3 cases had an ICG value of more than 20%. 60% of the whole group had liver cirrhosis, and the immunotherapy group was higher than the chemotherapy group; the former had 1 case of esophageal varices and the latter 3 cases. The study first performed LAK cell induction on fresh spleen cells.